GLP1R and type 2 diabetes mellitus: In patients with T2DM and clinical atherosclerosis (ASCVD), the combination of metformin with either an SGLT2 inhibitor or a GLP1-RA (AD1) is recommended to reduce cardiovascular events and to improve blood glucose control.